2021
DOI: 10.1136/bmjopen-2020-044747
|View full text |Cite
|
Sign up to set email alerts
|

PUTRA-Adol study: protocol for an observational follow-up study to assess the tracking of dietary patterns linked to cardiometabolic risk factors and its prospective relationship with non-alcoholic fatty liver disease, carotid intima-medial thickness and mental well-being during adolescence in Malaysia

Abstract: IntroductionGrowing evidence suggesting that dietary intakes of adolescents are generally of poor quality but not adequately assessed in relation to the early manifestation of non-communicable diseases. This study aimed; (1) to examine tracking of an empirical dietary pattern (DP) linked to cardiometabolic risk factors and, (2) to assess prospective relationships between a DP characterised by high intakes of dietary energy density (DED) and added sugar, and cardiometabolic risk factors, non-alcoholic fatty liv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 46 publications
0
1
0
Order By: Relevance
“…As reviewed in a meta-analyses and a systematic review, numerous clinical trials show that statin monotherapy reduces or even reverses the progression of CIMT [41,43,[44][45][46][47][48]. In terms of combination treatment with Ezetimibe, there was conflicting data initially with significant impact seen in the SANDS study (American Indians with diabetes) and the VYCTOR trial (high-risk Mexicans) consistent with LDL-C reduction and no impact in the ENHANCE study (Heterozygous Familial Hyperlipidemia) [49][50][51].…”
Section: Treatment Of Dyslipidaemia and Cimtmentioning
confidence: 99%
“…As reviewed in a meta-analyses and a systematic review, numerous clinical trials show that statin monotherapy reduces or even reverses the progression of CIMT [41,43,[44][45][46][47][48]. In terms of combination treatment with Ezetimibe, there was conflicting data initially with significant impact seen in the SANDS study (American Indians with diabetes) and the VYCTOR trial (high-risk Mexicans) consistent with LDL-C reduction and no impact in the ENHANCE study (Heterozygous Familial Hyperlipidemia) [49][50][51].…”
Section: Treatment Of Dyslipidaemia and Cimtmentioning
confidence: 99%